Mitochondrial DNA Defects
Mitochondrial DNA (mtDNA) defects are mutations in the circular genome contained within mitochondria, the cellular organelles responsible for energy production. The mitochondrial genome is small, encoding only 13 proteins essential for the electron transport chain, along with ribosomal and transfer RNAs required for protein synthesis. Mutations in mtDNA disrupt the production of ATP, the cell’s primary energy currency, resulting in impaired cellular energy metabolism.
Inheritance and Distribution
A key characteristic of mitochondrial DNA defects is maternal inheritance. Because mitochondria are transmitted almost exclusively through the egg cytoplasm, mtDNA mutations pass from mother to all offspring. However, the severity of disease can vary widely among siblings due to heteroplasmy—the presence of both mutant and wild-type mtDNA within cells and tissues. The proportion of mutant mtDNA (the mutation load) varies between cells and organs, leading to variable disease expression.
Clinical Manifestations
Mitochondrial DNA defects predominantly affect tissues with high energy demands, particularly the brain, muscle, heart, and eyes. Common syndromes include MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), MERRF (myoclonic epilepsy with ragged-red fibers), and Leber hereditary optic neuropathy (LHON). Symptoms typically emerge in childhood or early adulthood and may include muscle weakness, seizures, vision loss, cardiac dysfunction, and neurological decline.
Diagnosis and Management
Diagnosis involves genetic testing of mtDNA, muscle biopsy showing characteristic ragged-red fibers, and biochemical analysis revealing impaired oxidative metabolism. While no cure currently exists, management focuses on symptom relief and slowing disease progression through supportive care, lifestyle modifications, and targeted therapies addressing specific complications.